ACADIA Pharmaceuticals Inc
NASDAQ:ACAD

Watchlist Manager
ACADIA Pharmaceuticals Inc Logo
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
Watchlist
Price: 16.37 USD 1.17% Market Closed
Market Cap: 2.7B USD
Have any thoughts about
ACADIA Pharmaceuticals Inc?
Write Note

Intrinsic Value

The intrinsic value of one ACAD stock under the Base Case scenario is 19.77 USD. Compared to the current market price of 16.37 USD, ACADIA Pharmaceuticals Inc is Undervalued by 17%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ACAD Intrinsic Value
19.77 USD
Undervaluation 17%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ACADIA Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ACAD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ACAD?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about ACADIA Pharmaceuticals Inc

Provide an overview of the primary business activities
of ACADIA Pharmaceuticals Inc.

What unique competitive advantages
does ACADIA Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does ACADIA Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in ACADIA Pharmaceuticals Inc recently?

Summarize the latest earnings call
of ACADIA Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for ACADIA Pharmaceuticals Inc.

Provide P/S
for ACADIA Pharmaceuticals Inc.

Provide P/E
for ACADIA Pharmaceuticals Inc.

Provide P/OCF
for ACADIA Pharmaceuticals Inc.

Provide P/FCFE
for ACADIA Pharmaceuticals Inc.

Provide P/B
for ACADIA Pharmaceuticals Inc.

Provide EV/S
for ACADIA Pharmaceuticals Inc.

Provide EV/GP
for ACADIA Pharmaceuticals Inc.

Provide EV/EBITDA
for ACADIA Pharmaceuticals Inc.

Provide EV/EBIT
for ACADIA Pharmaceuticals Inc.

Provide EV/OCF
for ACADIA Pharmaceuticals Inc.

Provide EV/FCFF
for ACADIA Pharmaceuticals Inc.

Provide EV/IC
for ACADIA Pharmaceuticals Inc.

Show me price targets
for ACADIA Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for ACADIA Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for ACADIA Pharmaceuticals Inc?

What are the Net Income projections
for ACADIA Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for ACADIA Pharmaceuticals Inc?

What are the EPS projections
for ACADIA Pharmaceuticals Inc?

How accurate were the past EPS estimates
for ACADIA Pharmaceuticals Inc?

What are the EBIT projections
for ACADIA Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for ACADIA Pharmaceuticals Inc?

Compare the revenue forecasts
for ACADIA Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of ACADIA Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of ACADIA Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of ACADIA Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of ACADIA Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing ACADIA Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of ACADIA Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for ACADIA Pharmaceuticals Inc.

Provide ROE
for ACADIA Pharmaceuticals Inc.

Provide ROA
for ACADIA Pharmaceuticals Inc.

Provide ROIC
for ACADIA Pharmaceuticals Inc.

Provide ROCE
for ACADIA Pharmaceuticals Inc.

Provide Gross Margin
for ACADIA Pharmaceuticals Inc.

Provide Operating Margin
for ACADIA Pharmaceuticals Inc.

Provide Net Margin
for ACADIA Pharmaceuticals Inc.

Provide FCF Margin
for ACADIA Pharmaceuticals Inc.

Show all solvency ratios
for ACADIA Pharmaceuticals Inc.

Provide D/E Ratio
for ACADIA Pharmaceuticals Inc.

Provide D/A Ratio
for ACADIA Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for ACADIA Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for ACADIA Pharmaceuticals Inc.

Provide Quick Ratio
for ACADIA Pharmaceuticals Inc.

Provide Current Ratio
for ACADIA Pharmaceuticals Inc.

Provide Cash Ratio
for ACADIA Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for ACADIA Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for ACADIA Pharmaceuticals Inc?

What is the current Free Cash Flow
of ACADIA Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for ACADIA Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
ACADIA Pharmaceuticals Inc

Current Assets 788.3m
Cash & Short-Term Investments 565.3m
Receivables 110.4m
Other Current Assets 112.6m
Non-Current Assets 188.6m
PP&E 48.2m
Intangibles 105.5m
Other Non-Current Assets 34.8m
Current Liabilities 343.9m
Accounts Payable 19.1m
Accrued Liabilities 324.9m
Non-Current Liabilities 55.7m
Other Non-Current Liabilities 55.7m
Efficiency

Earnings Waterfall
ACADIA Pharmaceuticals Inc

Revenue
929.2m USD
Cost of Revenue
-77.9m USD
Gross Profit
851.3m USD
Operating Expenses
-739.1m USD
Operating Income
112.2m USD
Other Expenses
16.3m USD
Net Income
128.5m USD

Free Cash Flow Analysis
ACADIA Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Acadia Pharmaceuticals experienced a solid third quarter, generating $250.4 million in net sales, up 18% year-over-year. Key products include Daybue with sales of $91.2 million and NUPLAZID at $159.2 million, both seeing growth due to increased patient engagement. The company has narrowed its guidance for Daybue to $340-$350 million and NUPLAZID to $600-$610 million for the year. Notably, a $150 million priority review voucher sale is expected to enhance cash flow, projecting a cash balance increase to $600-$640 million. Promising pipeline assets like ACP-101 and ACP-204 are in late-stage trials, supporting potential future growth.

What is Earnings Call?
Fundamental Scores

ACAD Profitability Score
Profitability Due Diligence

ACADIA Pharmaceuticals Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROE is Increasing
ROIC is Increasing
41/100
Profitability
Score

ACADIA Pharmaceuticals Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

ACAD Solvency Score
Solvency Due Diligence

ACADIA Pharmaceuticals Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
60/100
Solvency
Score

ACADIA Pharmaceuticals Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ACAD Price Targets Summary
ACADIA Pharmaceuticals Inc

Wall Street analysts forecast ACAD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ACAD is 25.61 USD with a low forecast of 11.11 USD and a high forecast of 40.95 USD.

Lowest
Price Target
11.11 USD
32% Downside
Average
Price Target
25.61 USD
56% Upside
Highest
Price Target
40.95 USD
150% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ACAD?

Click here to dive deeper.

Dividends

ACADIA Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ACAD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ACAD Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

ACAD News

Other Videos

Profile

ACADIA Pharmaceuticals Inc Logo
ACADIA Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

2.7B USD

Dividend Yield

0%

Description

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 514 full-time employees. The company went IPO on 2004-05-27. The Company’s pipeline product candidates in CNS areas includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. The firm has initiated a Phase II study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery. The firm also initiated an additional Phase II study evaluating ACP-044 for the treatment of pain associated with osteoarthritis. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).

Contact

CALIFORNIA
San Diego
3611 Valley Centre Dr Ste 300
+18585582871.0
www.acadia-pharm.com

IPO

2004-05-27

Employees

514

Officers

Executive VP & CFO
Mr. Mark C. Schneyer
Executive VP, COO & Head of Commercial
Mr. Brendan P. Teehan
Consultant
Mr. Stephen R. Davis J.D.
CEO & Director
Ms. Catherine E. Owen Adams
VP, Chief Accounting Officer & Corporate Controller
Mr. James K. Kihara
Executive VP and Head of Research & Development
Dr. Elizabeth H.Z. Thompson Ph.D.
Show More
Senior Vice President of Technical Development, Operations & Quality
Mr. Benir Ruano
Senior Vice President of Investor Relations & Corporate Communications
Mr. Albert S. Kildani
Executive VP, Chief Legal Officer & Secretary
Ms. Jennifer J. Rhodes J.D.
Senior VP & Head of Sales
Ms. Holly Valdiviez
Show Less

See Also

Discover More
What is the Intrinsic Value of one ACAD stock?

The intrinsic value of one ACAD stock under the Base Case scenario is 19.77 USD.

Is ACAD stock undervalued or overvalued?

Compared to the current market price of 16.37 USD, ACADIA Pharmaceuticals Inc is Undervalued by 17%.

Back to Top